1. Home
  2. CTKB vs ZURA Comparison

CTKB vs ZURA Comparison

Compare CTKB & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytek Biosciences Inc.

CTKB

Cytek Biosciences Inc.

HOLD

Current Price

$4.32

Market Cap

652.1M

Sector

Health Care

ML Signal

HOLD

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$5.93

Market Cap

521.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTKB
ZURA
Founded
1990
2022
Country
United States
United States
Employees
N/A
30
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
652.1M
521.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CTKB
ZURA
Price
$4.32
$5.93
Analyst Decision
Hold
Strong Buy
Analyst Count
4
9
Target Price
$5.63
$11.78
AVG Volume (30 Days)
725.9K
475.6K
Earning Date
05-07-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$193,015,000.00
N/A
Revenue This Year
$5.42
N/A
Revenue Next Year
$7.03
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.67
N/A
52 Week Low
$2.37
$0.99
52 Week High
$6.18
$7.25

Technical Indicators

Market Signals
Indicator
CTKB
ZURA
Relative Strength Index (RSI) 44.29 46.38
Support Level $4.00 $5.62
Resistance Level $4.51 $6.99
Average True Range (ATR) 0.18 0.49
MACD 0.04 -0.09
Stochastic Oscillator 43.13 34.16

Price Performance

Historical Comparison
CTKB
ZURA

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Share on Social Networks: